Brief Description of the Company
The activities of ILKO İlaç in the sector are based on the pharmaceuticals that started with the production of magistral medicine in the 1960s by the late Mustafa Öncel, one of the second generation pharmacists of Turkey and one of the founders of the Turkish pharmaceutical industry, and then on his investments in the pharmaceutical sector.

ILKO Pharmaceuticals; With all its production and R&D investments, by using the advanced technologies needed by modern medicine, by offering "innovative" products that increase the quality of life of people and save lives; aims to be a leading company in global competition.

ILKO Pharmaceuticals has a wide product portfolio covering all major treatment areas, especially cardiology, central nervous system, rare diseases and acute products. It also operates in the fields of biotechnology and consumer health (with the Wellcare brand).

ILKO Pharmaceuticals Production Facilities, the construction of which started in 2009 and is the largest pharmaceutical production investment in Anatolia, started its operations in 2012. Production Facilities with the infrastructure to reach 120 million boxes; It has EU GMP, ISO 13485, ISO 45001, ISO 14001, ISO 27001, BS 10012, TSE Covid-19 Safe Production Place and Zero Waste certificates. ILKO Pharmaceuticals Production Facilities was established in 2013 by the T.C. It has been selected as 'Turkey's Cleanest Industrial Facility' by the Ministry of Environment and Urbanization.

ILKO Pharmaceuticals is focused on advanced technology and has the first and only production technologies in Turkey. 'Delayed-release Core-in Tablet Technology' (Chronopharmaceutical Product) and MUPS (Multiple Unit Pellet System/Multiple Unit Pellet System-Micropellet Technology) are only available at ILKO Pharmaceuticals.

ILKO Pharmaceuticals has a strong R&D structure and has two separate R&D Centers. Development of advanced technology and value-added products as well as small molecule generic products at the ILKO Argem R&D Center with a closed area of 2600 m2 in Hacettepe Technopark Work is also in progress.

ILKO Argem Biotechnology Center, which was established in 2014 and is Turkey's first biotechnology R&D Center, continues its activities to develop biotechnological drugs by using recombinant DNA technology as a tool. At the center, which aims to develop biotechnological products for cancer and cancer-related diseases in the first stage, R&D and clinical studies on biosuperior, biosimilar and new generation biotechnological products are still being carried out.

ILKO Pharmaceuticals is one of the 10 pharmaceutical companies that spend the most on R&D in Turkey. According to the results of the 'R&D 250 Research 2020' conducted by Turkishtime every year and covering all sectors, ILKO Pharmaceuticals was ranked 87th among the 500 companies with the highest R&D spending in 2020, and 10 pharmaceuticals in the 'Top 100'. became one of the companies.

ILKOGEN is Turkey's international joint investment in biotech pharmaceutical R&D, biosimilar and biosuperior product development and marketing. ILKOGEN started its operations in 2013 as a result of the combination of ILKO Pharmaceuticals' more than 50 years of production and marketing experience in the industry and the R&D expertise of South Korean biotechnology company Genexine in the field of biotechnology. ILKOGEN works to develop new generation biotechnology (biosuperior) and biosimilar drugs.Currently, three important projects are carried out in cooperation with universities and all three projects are supported by TUBITAK.

The Phase II clinical trial of GX-G3, the first original biotechnological drug of ILKO to be used in the treatment of chemotherapy-induced neutropenia, has been successfully completed. It is currently successfully continuing clinical studies of the best-in-class, long-acting, third generation G-CSF developed with Genexine's patented hyFc technology. In this context, it is planned to introduce the first İLKOGEN branded product to the market in the coming years.

One of Turkey's patent champions in the field of biotechnology is ILKO Pharmaceuticals. According to the results of the 'Turkey's Patent Report 2020 Research', ILKO Pharmaceuticals is among the companies that make the most patent applications in the field of biotechnology, in the 10th place in all sectors, and in the top 3 in the pharmaceutical sector.

LKO Pharmaceuticals; CIS carries out export activities in more than 25 countries in the Middle East, Balkans, Far East, Africa and Latin America regions and licensing activities in more than 40 countries.

ILKO Pharmaceuticals; In addition to its export activities, it is signing strategic cooperation with international companies within the scope of contracted production activities (CDMO / CMO).

Production Area
25,000  sqm closed area on 250.000 sqm land

Annual Production Capacity
The capacity of the plant has been planned for 120 million units per year on one shift, Current capacity is 25 million packs on one shift.

GMP Certificates
Turkey, EU (Malta), Iraq (KMCA+Kimedia), Uganda, Tanzania, Kenya, Ethiopia

Other Certificates
ISO 45001, ISO 14001, Medical Devices Quality Management System ISO 13485, ISO 27001, BS 10012, TSE Covid-19 Safe Production Place and Zero Waste certificates

Number of Employees
650